A network meta-analysis shows both PCSK9i and ezetimibe may reduce non-fatal MI and stroke in adults on maximum statin therapy or with statin intolerance who are at very high or high CVD risk but not in those at moderate or low risk.
Semaglutide reduces the risk of any first stroke in T2DM patients at high CVD risk, as revealed by an exploratory post-hoc analysis of the SUSTAIN 6 and PIONEER 6 trial . History of stroke had no influence on this effect.
In Japanese AF patients aged ≥80 years with high bleeding risk, edoxaban 15 mg reduced the incidence of stroke or systemic embolism across three age strata (80–84 years, 85–89 years, and ≥90 years), with no significant safety risk. Still, these results may not apply to other ethnic groups.
ACC 2022 Megan Coylewright gives her view on the results of the ADAPT-TAVR trial which investigated whether edoxaban, compared to DAPT can reduce leaflet thrombosis, cerebral thromboembolism and neurological/neurocognitive dysfunction after TAVR.
ACC 2022 The factor XIa inhibitor asundexian lowers bleeding rate compared with apixaban in patients with AF in the phase 2 PACIFIC-AF trial.
The results of an observational study suggest that treatment with DOAC may be associated with a positive net clinical benefit compared with VKA and no anticoagulation treatment in patients with AF at low stroke risk.
This study investigated the predictive value of a targeted plasma proteomics approach, analyzed with machine learning techniques in a secondary prevention setting.
A nested case-control study with a proteomic approach identified programmed cell death 1 ligand 2 (PD-L2) as a potential novel biomarker of ischemic stroke/systemic embolic event risk in patients with AF who were enrolled in the ENGAGE AF-TIMI 48 trial.
No significant interaction was found on treatment effect of apixaban vs. VKA or aspirin vs. placebo across HAS-BLED or CHA2DS-VASc categories in patients with AF in the first 6 months following an ACS and/or PCI, in a post hoc analysis of the AUGUSTUS trial.
In the CHANCE-2 trial, treatment with ticagrelor and aspirin reduces recurrent stroke at 90 days compared to use of clopidogrel and aspirin in Chinese patients with minor ischemic stroke or TIA who are carriers of CYP2C19 LOF alleles. Risk of severe or moderate bleeding was…
EASD 2021 In patients with diabetes, included in the Hoorn Diabetes Care System cohort, measures of kidney disease, eGFR and UACR, were differentially associated with subtypes of CVD.
ESC 2021 Prof. Casadei gives her opinion about what we should do with the evidence from the Salt Substitute and Stroke Study (SSaSS), which showed that switching to a salt substitute reduces the risk of stroke, CV events and death.